Moderna raises 2025 revenue forecast to $1.9 billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026 7:00 AM ESTExpects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings Call
Improves 2025 expected GAAP operating expenses by $200 million since 3Q25 Earnings Call
Increases 2025 projected year-end cash balance to approximately $8.1 billion (unaudited)
Reiterates plan to deliver up to 10% revenue growth and GAAP operating expense reductions in 2026
Anticipates potential first approvals of flu and flu/COVID combination products in 2026
Expects pivotal trial data readouts in oncology, rare disease and infectious disease in 2026
CAMBRIDGE,... More
